Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman.
Eur J Contracept Reprod Health Care
; 20(3): 231-5, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-25798535
ABSTRACT
OBJECTIVE:
The study aimed to investigate the effect of concomitant use of atorvastatin or rosuvastatin on the pharmacokinetic and pharmacodynamic profile of centchroman, a non-steroidal female oral contraceptive.METHODS:
A rat model was used to predict pharmacokinetic drug-drug interactions between centchroman and atorvastatin or rosuvastatin. A dried blood spot sampling technique followed by liquid chromatography-tandem mass spectrometry detection was employed for analysis of the pharmacokinetic interaction study samples. Sperm-positive female rats were investigated for postcoital contraceptive activity of centchroman with or without coadministration of atorvastatin or rosuvastatin.RESULTS:
Coadministration of atorvastatin or rosuvastatin may increase the systemic availability of centchroman in blood, but it does not affect the pharmacodynamic profile of centchroman.CONCLUSION:
Atorvastatin or rosuvastatin may be prescribed with centchroman without compromising the contraceptive efficacy of centchroman.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Centocromano
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Anticoncepcionais Sintéticos Pós-Coito
/
Rosuvastatina Cálcica
/
Atorvastatina
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Eur J Contracept Reprod Health Care
Assunto da revista:
MEDICINA REPRODUTIVA
/
SERVICOS DE PLANEJAMENTO FAMILIAR
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Índia